Trial Profile
A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan 160 mg alone for 8 weeks in hypertensive patients who are not adequately controlled on valsartan 160 mg monotherapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Amlodipine/valsartan (Primary) ; Valsartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 07 Nov 2011 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
- 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2011 This trial is completed in Latvia and Lithuania.